Results 141 to 150 of about 91,122 (346)

Genetic and Pathological Testing Attitudes for Parkinson's Disease in At‐Risk Relatives

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is increasingly recognized as a neurodegenerative disorder with a broad clinical spectrum and diverse biomarkers enabling early detection. α‐synuclein seed amplification assays (SAA) and genetic testing now allow identification of PD pathology in asymptomatic individuals.
Tal Weil, Anat Mirelman, Roy N. Alcalay, Nurit Omer, Penina Ponger, Avner Thaler   +5 more
wiley   +1 more source

Dementia With Lewy Bodies: A Review of Disease-Modifying Therapies for α-Synucleinopathies

BJPsych Open
Aims: The global demographic transition has led to a growing ageing population. Neurodegenerative disease prevalence is high in the elderly, as aged brains accumulate molecular and cellular damage.
Arzoo Dar, Sharmi Bhattacharyya
doaj   +1 more source

A Biomarker‐Based Classification of Corticobasal Syndrome

Movement Disorders, EarlyView.
Abstract Background Corticobasal syndrome (CBS) is a clinically defined syndrome with progressive movement and cortical dysfunction, caused by various underlying pathologies, most commonly tau‐predominant pathologies such as progressive supranuclear palsy and corticobasal degeneration, or Alzheimer's disease (AD).
Carla Palleis, Alexander Maximilian Bernhardt, Endy Weidinger, Urban M. Fietzek, Alexander Jäck, Sabrina Katzdobler, Johannes Gnörich, Theresa Bauer, Nicolai Franzmeier, Robert Perneczky, German Imaging Initiative for Tauopathies (GII4T), Matthias Brendel, Johannes Levin, Günter U. Höglinger   +13 more
wiley   +1 more source

Getting to the heart of Lewy body disease

The Journal of Clinical Investigation
Early identification of neurodegenerative diseases before extensive neuronal loss or disabling symptoms have occurred is imperative for effective use of disease-modifying therapies.
Anna E. Goodheart, Craig Blackstone
doaj   +1 more source

Neuroinflammation is associated with infiltration of T cells in Lewy body disease and ɑ-synuclein transgenic models.

, 2020
Michiyo Iba, Changyoun Kim, Michelle A. Sallin, Somin Kwon, Anjali Verma, Cassia Overk, Robert A. Rissman, Ranjan Sen, Jyoti Misra Sen, Eliezer Masliah   +9 more
openalex   +1 more source

Rare but Relevant? Assessing Variants in Dystonia‐Linked Genes in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Dystonia and Parkinson's disease (PD) exhibit clinical and genetic overlap, but the relevance of dystonia gene variants in PD remains unclear. Objective The aim was to assess the frequency of dystonia‐linked pathogenic variants in PD.
Lara M. Lange, Zih‐Hua Fang, Laurel Screven, Ai Huey Tan, Roy N. Alcalay, Rim Amouri, Roberta Bovenzi, Matilda Fenn, Joshua L.I. Frost, Joseph Jankovic, Simona Jasaityte, Zane Jaunmuktane, Beomseok Jeon, Ignacio Juan Keller Sarmiento, Rejko Krüger, Gregor Kuhlenbäumer, Chin‐Hsien Lin, Lukas Pavelka, Maria Teresa Periñan, Samia Ben Sassi, Tommaso Schirinzi, Jung Hwan Shin, Joshua M. Shulman, Yi Wen Tay, Ryan Uitti, Tom Warner, Zbigniew K. Wszolek, Lesley Wu, Ruey‐Meei Wu, Kirsten E. Zeuner, Cornelis Blauwendraat, Andrew Singleton, Niccolò E. Mencacci, Huw R. Morris, Shen‐Yang Lim, Katja Lohmann, Christine Klein, the Global Parkinson's Genetics Program (GP2)   +37 more
wiley   +1 more source

Electron microscopy analysis of alpha-synuclein and LRRK2 transgenic C. elegans [PDF]

, 2013
Thesis (M.A.)--Boston UniversityMutations in alpha-synuclein and leucine-rich repeat kinase 2 (LRRK2) have been implicated in the cause of Parkinson’s disease (PD).
Nguyen, Andrew Huy
core   +1 more source

Beyond Pathology: α‐Synuclein Homeostasis and Three Principles to Guide Research

Movement Disorders Clinical Practice, EarlyView.
Alberto J. Espay, Andrew J. Lees
wiley   +1 more source

LRRK2 as a Potential Disease‐Modifying Target in Sporadic Parkinson's Disease

Movement Disorders, EarlyView.
Abstract A growing understanding of the role that leucine‐rich repeat kinase 2 (LRRK2) plays in Parkinson's disease (PD) supports continued focus on this enzyme as a therapeutic target for PD. Accumulating evidence suggests that there are phenotypic, neuropathologic, and biological similarities between sporadic PD (sPD) and familial forms in which ...
Anthony E. Lang, Robert A. Hauser, Lorraine V. Kalia, Bonnie Hersh, Zdenek Berger, Roy Llorens Arenas, Coro Paisan‐Ruiz, Kyle Fraser, Danna Jennings, Jillian H. Kluss, Sarah Huntwork‐Rodriguez, Anastasia G. Henry, J. Timothy Greenamyre   +12 more
wiley   +1 more source

Differential Effects of Tau Stage, Lewy Body Pathology, and Substantia Nigra Degeneration on¹⁸F-FDG PET Patterns in Clinical Alzheimer Disease [PDF]

, 2022
Jesús Silva‐Rodríguez, Miguel A. Labrador‐Espinosa, Alexis Moscoso, Michael Schöll, Pablo Mir, Michel J. Grothe, for the Alzheimer’s Disease Neuroimaging Initiative   +6 more
openalex   +1 more source